Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Agrawal, Manasi
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Brenner, Erica J
    • Affiliation: School of Medicine, Department of Pediatrics
  • Zhang, Xian
    • Affiliation: School of Medicine, Department of Pediatrics
  • Modesto, Irene
    • Other Affiliation: Pfizer Inc
  • Woolcott, John
    • Other Affiliation: Pfizer Inc
  • Ungaro, Ryan C
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Colombel, Jean-Frederic
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Kappelman, Michael D
    • Affiliation: School of Medicine, Department of Pediatrics
Abstract
  • The coronavirus disease 2019 (COVID-19) pandemic due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to unprecedented loss of life and health on a global scale. COVID-19 outcomes are more severe among those with comorbid conditions, which raises concerns for patients with inflammatory bowel disease (IBD), especially given the increased infection risk with immunosuppression used for IBD therapy.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Inflammatory Bowel Diseases
Language
  • English
Version
  • Publisher

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details izaa303.pdf 2021-01-04 Public Download